Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, and supported by existing investors, bringing the total funding to $60 million.
The investment enables it to further deploy its AI algorithms for the prospective enrollment of patients in clinical trials – a first in the field and a significant advancement in personalized solutions tailored to the distinct needs of patients.
Read also – India-based SiftHub Raises $5.5 Million in Seed Round Funding
The funding exemplifies it’s growing momentum in the life sciences industry, evidenced by collaborations with over 60 percent of the top 20 biopharma companies, venture backing from renowned investors like Section 32 and Sanofi Ventures, and now with M Ventures.
The funding will accelerate the deployment of Nucleai’s spatial analysis technology that transforms a static biopsy slide into a dynamic AI-guided action plan, empowering pathologists with the intelligence to anticipate and navigate complex diseases, like cancer, with unmatched precision.
Read also – Inc. Arabia Collaborates with EntArabi to Improve the Arab Entrepreneurial Landscape
Nucleai’s platform tailors therapy strategies to the intricate cellular landscape of each patient, optimizing clinical trial participant selection. This personalized approach not only improves the likelihood of successful clinical outcomes but also significantly contributes to the speed and efficiency of bringing new therapies to market.
About Nucleai
Nucleai is precision medicine through the use of spatial biology technologies to enhance patient outcomes, clinical treatment choices, and drug development. Nucleai collaborates on biomarkers discovery initiatives and licenses its research platform for internal use with top pharmaceutical companies.
